CuttsRConnorMJSunL, et al. Mesothelioma subtypes of the tunica vaginalis: A rare case report and review of histological criteria. J Surg Case Rep2019; 2019: rjz040.
2.
RecabalPRosenzweigBBazziWM, et al. Malignant mesothelioma of the tunica vaginalis testis: Outcomes following surgical management beyond radical orchiectomy. Urology2017; 107: 166–170.
3.
BrimoFIlleiPBEpsteinJI.Mesothelioma of the tunica vaginalis: A series of eight cases with uncertain malignant potential. Mod Pathol2010; 23: 1165–1172.
4.
MezeiGChangETMowatFS, et al. Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis. Ann Epidemiol2017; 27: 348–359.e311.
5.
MensiCPellegattaMSienoC, et al. Mesothelioma of tunica vaginalis testis and asbestos exposure. BJU Int2012; 110: 533–537.
6.
Perez-OrdonezBSrigleyJR.Mesothelial lesions of the paratesticular region. Semin Diagn Pathol2000; 17: 294–306.
7.
PlasERiedlCRPflügerH.Malignant mesothelioma of the tunica vaginalis testis: Review of the literature and assessment of prognostic parameters. Cancer1998; 83: 2437–2446.
VogelzangNJRusthovenJJSymanowskiJ, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol2003; 21: 2636–2644.
10.
JonesMAYoungRHScullyRE.Malignant mesothelioma of the tunica vaginalis. A clinicopathologic analysis of 11 cases with review of the literature. Am J Surg Pathol1995; 19: 815–825.
11.
AlleyEWLopezJSantoroA, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol2017; 18: 623–630.
12.
HassanRThomasANemunaitisJJ, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN Solid Tumor Trial. JAMA Oncol2019; 5: 351–357.
